🔴 OTLK is trading 5.1% down today as traders take profits following its recent FDA-driven rally

OTLK is trading at $1.59 (down 5.1%) as the stock experiences a pullback following a significant rally sparked by positive regulatory news.

• The recent surge was driven by the FDA's acceptance of the resubmitted Biologics License Application (BLA) for Lytenava, with a PDUFA goal date set for July 29, 2026.
• Today's decline appears to be a continuation of the rally cooling off as investors lock in gains rather than a reaction to fresh company-specific news.
• The stock remains a focal point for traders monitoring the long-term regulatory timeline for its ophthalmic formulation.